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The  targeted  inhibition  of  epidermal  growth  factor  receptor  (EGFR)  has  represented  a milestone  in the
treatment  of lung  cancer.  Several  studies  convincingly  and  consistently  demonstrated  a signiﬁcant  supe-
riority  of  EGFR-TKIs  over  standard  platinum-chemotherapy  in EGFR-mutated  NSCLC  patients,  leading  to
the sequential  approval  of  geﬁtinib,  erlotinib  and  afatinib  as  new  standard  ﬁrst-line  clinical  treatment.
To  date  we  are  witnessing  a  second  revolution  in  the  management  of EGFR-positive  NSCLC  thanks  to theGFR
argeted therapy
KIs
esistance
iquid biopsy
development  of new  treatment  strategies  aiming  to overcome  acquired  resistance  to TKIs  and  ultimately
improve  patients’  outcomes.  In this  review  we summarize  the  most  important  recent  ﬁndings  regarding
EGFR-inhibition  in NSCLC,  highlighting  the current  unsolved  questions  on the  selection  of the  best  TKI  in
ﬁrst-line,  which  therapy  can  be combined  with  upfront  EGFR-TKIs,  how  to overcome  acquired  resistance,
and  which  are  the  clinical  applications  of  liquid  biopsy.
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The pharmacological inhibition of the epidermal growth factor
receptor (EGFR) by tyrosine-kinase inhibitors (TKIs) represented
the ﬁrst example of successful targeted therapy in lung cancer.
The discovery of EGFR activating mutations in 2004 as oncogene
driver in a subgroup of patients with non-small cell lung can-
cer (NSCLC) led to the development of a new family of biological
agents, called EGFR-TKIs, which were able to selectively bind and
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nhibit the EGFR molecular pathway (Bronte et al., 2014). Since the
pproval of the ﬁrst EGFR-TKI geﬁtinib in clinical setting, several
ther compounds have been developed by pharma, which may  be
lassiﬁed as ﬁrst, second, and third-generation EGFR-TKIs. About
ight phase III randomized clinical trials compared EGFR-TKI Geﬁ-
inib, Erlotinib, or Afatinib vs platinum-based chemotherapy as
rst-line treatment for EGFR-mutated NSCLC patients (Reis-Filho
nd Pusztai, 2011; Mitsudomi et al., 2010; Maemondo et al., 2010;
az-Ares et al., 2017a; Network CGA, 2012; Zhou et al., 2011;
equist et al., 2011; Wu  et al., 2014). The results of all such studies
onvincingly and consistently demonstrated a signiﬁcant superior-
ty of EGFR-TKIs over standard platinum-chemotherapy, improving
oth response rate (RR), progression free survival (PFS) and qual-
ty of life (QoL) of EGFR-mutated NSCLC patients. These positive
esults have led to the sequential approval by regulatory author-
ties of geﬁtinib, erlotinib and afatinib as upfront treatment of
GFR-mutated NSCLC patients. The advent of targeted agents in
linical setting has certainly represented one of the most impor-
ant innovations in the treatment of lung cancer over the last years.
hese drugs have revolutioned the clinical management of about
0% Asian and 12% Caucasian NSCLC patients harboring EGFR-
utations, whose survival outcomes nearly doubled compared to
tandard chemotherapy. However, the development of resistance
as signiﬁcantly limited the potential beneﬁt of these drugs. Indeed
he majority of patients have a disease progression (PD) within one
ear of TKI therapy (Passiglia et al., 2015). Recent studies suggested
ew treatment strategies to overcome resistance and ultimately
mprove survival outcomes of EGFR-mutated patients, thus leaving
ome questions unsolved:
 How to decide which TKI in ﬁrst line?
 Which therapy can be combined with EGFR-TKIs to improve
patients outcomes?
 How to overcome acquired resistance to EGFR-TKIs?
 Which is the current role of liquid biopsy?
In this review we highlight all most recent important ﬁndings
egarding EGFR-inhibition in NSCLC, trying to provide evidence-
ased answers to the aforementioned questions.
. How to decide which TKI in ﬁrst line?
.1. Indirect comparisons
To date we have three EGFR-TKIs approved as ﬁrst-line treat-
ent for EGFR-mutated NSCLC patients. Two ﬁrst-generation,
eversible TKIs, geﬁtinib and erlotinib, and one second-generation,
rreversible, pan-Her TKI, afatinib. These compounds have shown
imilar efﬁcacy in studies and meta-analysis which indirectly com-
ared them, reaching an efﬁcacy plateau in both PFS (10–12
onths) and OS (ranging from 21 to 30 months) (Haspinger et al.,
015). Afatinib is the only compound showing a signiﬁcant OS
eneﬁt in the recent pooled analysis of both LuxLung3 (LL3) and
uxLung6 (LL6) trials, even if limited to the subgroup of patients
ith EGFR exon 19 deletion (Yang et al., 2015a). Furthermore it is
he TKI with more evidence-based activity against EGFR uncom-
on  mutations (Yang et al., 2015c). Particularly it showed to be
ctive against the most frequent uncommon mutations, includ-
ng Gly719Xaa, Leu861Gln, and Ser768Ile, while very low activity
as been demonstrated in other mutation types, such as de-novo
hr790Met mutation or insertions in exon 20. Even if limited by
he low number of patients analyzed, erlotinib also demonstrated
ctivity in patients harboring uncommon EGFR mutations. In detail,
xon 18 G719 mutations, exon 19 K757R and E746G mutations,
xon 20 S768I and exon 21 G836S mutations have been associ-gy/Hematology 112 (2017) 126–135 127
ated with good clinical outcomes, whereas tumors harboring exon
18 S720I mutation had poor responses to erlotinib (Klughammer
et al., 2016). Besides this, potential differences in tolerability proﬁle,
drugs’ interactions and costs are usually taken into account in order
to select the best drug for each patient. As regards toxicity, skin rash
and diarrhea were the most common adverse events (AEs) reported
with all EGFR-TKIs, with a higher percentage observed with afatinib
than erlotinib or geﬁtinib, while the risk of elevated transaminases
was higher for geﬁtinib compared to the other TKIs. The percentage
of grade (G) 3–4 AEs was higher with erlotinib (54.1%), than afatinib
(42.1%) or geﬁtinib (29.1%), while no differences in drug-related
AEs discontinuation has been observed between the different TKIs
(Ding et al., 2016). Furthermore the safety proﬁles of all three EGFR-
TKIs became similar if evaluated after an immediate and proactive
management of emerging toxicities (Passaro et al., 2014). A post-
hoc analysis including about 500 patients included in both LL3 and
LL6 studies reported a dose-reduction of afatinib from 40 mg  to
30 mg  or from 30 mg  to 20 mg  in about 50% and 30% of patients
respectively, usually occurring within 6 months of TKI therapy. The
dose-adjustment was  associated with a signiﬁcant decrease of both
all grade and G3-4 AEs, without any inﬂuence on treatment bene-
ﬁt (Yang et al., 2016a). These evidences support the possibility to
modulate the dose of afatinib according to the patients’ tolerability
during the treatment course, facilitating the clinical management
of patients’ toxicities, without inﬂuencing treatment efﬁcacy.
2.2. Direct comparisons
Recently the LuxLung7 (LL7) study ﬁrst performed a “head
to head” comparison between ﬁrst-generation TKI geﬁtinib and
second-generation TKI afatinib in ﬁrst-line treatment of EGFR-
mutated NSCLC. LL7 is a randomized prospective phase IIb study,
including three co-primary end-points, such as PFS, time to treat-
ment failure (TTF), and OS. The results of the study have shown a
signiﬁcant superiority of afatinib over geﬁtinib both in PFS (11 vs
10,9 months; HR: 0.74, 95%CI: 0.57–0.95, p: 0.017) and TTF (13.7
vs 11.5 months; HR: 0.73, 95%CI: 0.58–0.92, p: 0.007), regardless
from the speciﬁc type of EGFR activating mutation (Del19 vs L858R)
(Park et al., 2016a). A signiﬁcant increment of RR has been also
reported with afatinib (73% vs 56%, p: 0.002). However it has not
been translated into an OS beneﬁt. Indeed at a median follow-up
of 42.6 months only a trend toward a better OS  has been observed
in patients receiving afatinib (27.9 vs 24.5 months) which did not
reach statistical signiﬁcance (HR: 0.86, 95%CI: 0.66–1.12) (Paz-Ares
et al., 2017b). Even if OS data are still immature, LL7 can be formally
deﬁned as a negative trial. However we should take into account
that such study has met  two  (PFS and TTF) of the three co-primary
endpoints, overall showing a signiﬁcant reduction of 25% in the
risk of PD, with about ¼ of patients reaching a signiﬁcant PFS ben-
eﬁt >6 months with afatinib. Both TTF and PFS as well as OS data
reported in LL7 are similar and consistent to those observed in other
randomized studies of afatinib in ﬁrst-line (Sequist et al., 2013; Wu
et al., 2014), suggesting a potential superiority of this drug. Fur-
thermore we can’t exclude that ﬁnal OS data, including also late
censored events, might reach the statistical signiﬁcance, deﬁni-
tively conﬁrming the beneﬁt observed in both PFS and TTF, which
usually are more informative about ﬁrst-line treatment efﬁcacy.
As regards safety, both drugs were well tolerated with an overall
incidence of G > 3 AEs of 30% with afatinib and 20% with geﬁtinib,
and very low percentages (6%) of treatment discontinuations due to
drug-related AEs in both treatment arms. A signiﬁcant higher rate
of diarrhea (90%) and stomatitis (64%) have been reported with
afatinib, while transaminases increase was more frequent with
geﬁtinib (24%). Furthermore about 4 cases of severe interstitial lung
disease have been described in geﬁtinib arm (Park et al., 2016a).
ARCHER-1050, NCT01774721, is another ongoing study compar-
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ng ﬁrst vs second-generation EGFR-TKI (geﬁtinib vs dacomitinib),
ut results are not available yet. CTONG 0901 is a phase II study
f erlotinib vs geﬁtinib which didn’t show any signiﬁcant survival
ifferences between the two treatment arms (Yang et al., 2015b).
inally the impressive efﬁcacy results observed with the third-
eneration EGFR-TKI osimertinib in the ﬁrst-line cohort of AURA
tudy (RR: 77%, PFS: 19.7 months) (Ramalingam et al., 2016) have
ed to the design of the randomized phase III FLAURA trial. This
s the ﬁrst study comparing third-generation TKI osimertinib vs
rst-generation TKI geﬁtinib or erlotinib as ﬁrst-line treatment of
GFR-mutated NSCLC patients, and the results of such trial are
agerly awaited because they could further modify the current
reatment algorithm in this subgroup of patients. To date all evi-
ences available about EGFR-TKIs’ efﬁcacy and tolerability should
e carefully evaluated by clinicians in order to select the best drug
or each patients in everyday clinical practice.
.3. Activity against brain metastasis
Brain metastasis (BM) are a common event in EGFR-mutated
SCLC, with major negative impact on patients’ QoL and survival,
anging from 4.5 months to 11.0 months after diagnosis (Liao et al.,
015; Umemura et al., 2012). Current treatment options available
or EGFR-mutated patients with BM are very limited, also because
heir participation in prospective clinical trials was  historically very
ow. Stereotactic radiosurgery (SRS) and whole brain radiother-
py (WBRT) concomitantly or followed by EGFR-TKIs remain the
urrent gold standard for patients with BM,  even if they are often
ssociated with considerable adverse neurotoxicity and question-
ble efﬁcacy. Activity of upfront ﬁrst-generation EGFR-TKIs has
een reported in retrospective series including low number of East-
sian patients (Park et al., 2012; Iuchi et al., 2013; Gerber et al.,
014; Zhang et al., 2016a), overall showing poor response rates
ikely due to the low penetration of such agents across the blood-
rain barrier (BBB) (Zhao et al., 2013; de Vries et al., 2012). Some
tudies showed that erlotinib has a better central nervous sys-
em (CNS) penetration than geﬁtinib (Togashi et al., 2012), thus
uggesting that it could be preferred if TKI monotherapy is used
pfront for asymptomatic patients with BM.  However a retrospec-
ive multi-Institutional analysis has recently demonstrated that the
se of upfront EGFR-TKI and deferral of radiotherapy is associ-
ted with inferior OS, suggesting that radiotherapy followed by TKI
hould be considered as the preferred strategy (Magnuson et al.,
017). Encouraging data emerged from the phase I BLOOM study
ncluding EGFR-mutated NSCLC patients progressed on prior treat-
ent with EGFR-TKI with a conﬁrmed diagnosis of BM.  Among
he 21 patients receiving osimertinib 160 mg  daily, 33% had PR
nd 43% had SD, with a tolerable safety proﬁle including only
4% G ≥ 3 drug-related AEs (Yang et al., 2016b). Waiting for the
esults in the T790M-positive cohort included in the BLOOM study,
simertinib has already shown high activity in patients with CNS
isease harboring T790M mutation enrolled in two phase II studies
Goss, 2017), likely due to its greater penetration of animal mod-
ls’ BBB compared to other TKIs, geﬁtinib, rociletinib, or afatinib
Ballard et al., 2016). Furthermore the recent results of the AURA
 trial demonstrated a signiﬁcant survival beneﬁt of osimertinib
ver platinum-chemotherapy in 144 T790M-positive patients with
NS metastasis at baseline, suggesting it as a very effective drug
or these patients (Mok  et al., 2017). Recently the results of the
rst prospective randomized trial comparing EGFR-TKI icotinib vs
BRT ± chemotherapy in EGFR-mutated asian NSCLC patients with
M,  have shown a signiﬁcant superiority of TKI in terms of both
ntracranial and systemic RR, as well as intracranial and systemic
FS, together with a lower incidence of severe treatment-related
Es (Wu et al., 2017). These data suggest icotinib as new standard
-line treatment for EGFR-positive asian patients with BM.  How-gy/Hematology 112 (2017) 126–135
ever data on OS, neurotoxicity and secondary use of WBRT are not
available yet. Furthermore it will be useful to see the results of other
two ongoing randomized phase III trials comparing upfront EGFR-
TKI erlotinib or geﬁtinib vs WBRT (NCT02714010; NCT02338011)
including also caucasian population, as well as a potential com-
parison between third-generation TKI osimertinib vs WBRT, before
to modify current treatment recommendations in this setting of
patients.
3. Which therapy can be combined with EGFR-TKIs to
improve patients’ outcomes?
3.1. Anti-angiogenic agents
Pre-clinical studies have shown a close biological link between
EGFR and angiogenetic pathways, likely mediated by signal trans-
ducer and activator of transcription 3 (STAT3), which plays a
crucial role in the tumor angiogenesis (Hall et al., 2015). A recent
study demonstrated that EGFR-mutated NSCLC cell-lines and tis-
sues are associated with increased expression of VEGF and that
EGFR-inhibition reduces VEGF levels (Hung et al., 2016). Recently
the addition of bevacizumab to the EGFR-TKI, Erlotinib, has been
investigated in a phase II randomized study including untreated,
EGFR-mutated, East-Asian NSCLC patients. The results of such study
showed a signiﬁcant longer median PFS (16 vs 9.7 months), with
about 50% reduction of the risk of progression (HR: 0.54 (95%CI:
0.36–0.79)) in favour of the combination arm (Seto et al., 2014).
Interestingly the preliminary results of the European BELIEF trial
have recently revealed that patients with EGFR-T790M positive
tumors would beneﬁt more from erlotinib plus bevacizumab com-
bination with a median PFS of 16 months compared to 10.5 months
of patients without T790M, suggesting a new potential strategy
to overcome T790M-mediated acquired resistance (Stahel et al.,
2015). The major concern for clinical use is represented by the
cumulative toxicity, whit about 60% of G3-4 hypertension and 8%
of G3-4 proteinuria reported in the combination arm, while no dif-
ferences in drug-discontinuation rate have been observed between
the two  treatments. On the basis of these positive results erlotinib
plus bevacizumab has recently received the approval in ﬁrst-line by
both Food and Drug Administration (FDA) and European Medical
Agency (EMA), emerging as new frontline backbone for EGFR-
mutated NSCLC patients. Although these data are very promising,
we would like to see the results of the conﬁrmatory ongoing phase
III NEJ026 (Maemondo et al., 2016) and BEVERLY (Gridelli et al.,
2016) studies, including Asian and Caucasian patients respectively,
before to start using this combination in clinical practice. Similarly
the phase III RELAY trial (NCT02411448) is currently investigating
ramucirumab in combination with erlotinib vs erlotinib alone as
ﬁrst-line treatment in about 400 EGFR mutated NSCLC patients, but
we expect ﬁnal results that will be available within the two next
years.
3.2. Chemotherapy
Several phase III studies evaluated the addition of chemother-
apy to EGFR-TKIs in ﬁrst-line (Gatzemeier et al., 2007; Giaccone
et al., 2004; Herbst et al., 2004; Herbst et al., 2005; Jänne et al.,
2012), demonstrating no survival beneﬁt with combinations, likely
because wild-type patients were also enrolled. The FASTACT2 ran-
domized phase III study subsequently showed that the signiﬁcant
improvement of survival outcomes obtained with a ﬁrst-line inter-
calated regimen of chemotherapy and erlotinib combination was
only limited to the subgroup of patients with an activating EGFR-
mutation (Wu et al., 2013).
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Recently Ying Cheng and colleagues reported the results of a
hase II randomized trial comparing pemetrexed plus geﬁtinib vs
eﬁtinib in treatment-naive, East Asian patients, with advanced
SCLC and activating EGFR mutations. The study met its primary
nd-point in the intent-to-treat population, showing a signiﬁcantly
onger median PFS in favour of the combination arm (15.8 vs
0.9 months; HR: 0.68; 95%CI: 0.48-–0.96), independently from
he speciﬁc type of mutation (EGFR exon 19 deletion vs L858R
utation), while no differences in response rate (RR: 80% vs 74%)
ere observed between the two treatment arms. As attended,
he percentage of patients who reported G3-4 drug-related AEs
as signiﬁcantly higher (42% vs 19%) in the combination arm as
ell as the proportion of patients who discontinued treatment
Cheng et al., 2016). Similarly the NEJ005 randomized phase II
tudy, prospectively compared concurrent geﬁtinib plus carbo-
latin/pemetrexed regimen vs sequential alternating regimen in
ast-Asian, EGFR-mutated NSCLC patients. The results of such study
howed a favorable trend in PFS (18.3 vs 15.3 months; HR 0.71, 95%
I 0.42–1.20; P = 0.20) and a signiﬁcant improvement in OS (41.9 vs
0.7 months; HR 0.51, 95% CI 0.26–0.99; P = 0.042), in favour of the
oncurrent regimen arm (Sugawara et al., 2015), demonstrating the
uperiority of the upfront combination of TKI plus chemo, which is
urrently investigated in the ongoing phase III study. Both such
rials suggested that adding chemotherapy to EGFR-TKI in ﬁrst-
ine may  improve outcomes of EGFR-mutated patients. The beneﬁt
btained could be likely related to the activity of early concurrent
se of cytotoxic agents against de-novo resistance alterations, but
he lack of tissue samples collection for biomarker analysis, limited
he possibility to evaluate molecular data. The results are intriguing,
ut need to be conﬁrmed by prospective phase III ongoing studies,
ncluding both Asian and Caucasian populations, in order to eval-
ate the optimal treatment sequence, and ultimately accept the
ncreased adverse events and cost of an upfront combination.
.3. Immunotherapy
Constitutive oncogenic signaling through the EGFR pathway
romotes programmed death ligand 1 (PDL1) expression and
reatment with PD1 inhibitors may  enhance tumor responses
n EGFR-mutated pre-clinical models (Akbay et al., 2013; Chen
t al., 2015). However the majority of clinical trials of immune-
heckpoint inhibitors (ICI) in lung cancer have shown that single
gent ICIs are not effective in pre-treated NSCLC patients harbor-
ng EGFR-mutations, discouraging their clinical use in this subgroup
f patients. A recent meta-analysis also conﬁrmed that PD1/PDL1
nhibitors don’t improve OS compared to docetaxel in pre-treated,
GFR-mutated NSCLC patients (Lee et al., 2017 Feb). Translational
tudies clearly demonstrated that NSCLC with oncogene drivers,
ncluding both EGFR activating and resistant mutations, are char-
cterized by a very low tumor mutation burden (TMB), which is
ommonly considered as good predictor of response to ICI therapy
Spigel et al., 2016; Rizvi et al., 2015). Even if EGFR-mutated tumors
re often associated with PDL1 overexpression (D’Incecco et al.,
015), the low rate of tumor inﬁltrate lymphocytes (TILs) suggests
 very low immune-dependence of these tumors. Recently Gainor
t al. have found a concurrent PD-L1 overexpression and high rate
f TILs in the tumor microenvironment of only 1/57 TKI-naive and
/57 TKI- resistant patients with EGFR-mutated NSCLC (Gainor
t al., 2016), conﬁrming a lack of immunogenicity in the major-
ty of such tumors. Even if PD-L1 expression levels changed in 16
atients evaluated after EGFR-TKI therapy, however not signiﬁcant
ariations in both TILs and PDL1 expression have been found before
nd after TKI. Despite these translational evidences, the results
f the phase II BIRCH study have recently demonstrated a great
ctivity of atezolizumab monotherapy as ﬁrst-line treatment in
DL1-positive NSCLC patients, regardless of tumor EGFR-mutationgy/Hematology 112 (2017) 126–135 129
status(Garassino et al., 2017). Several trials are currently inves-
tigating the potential beneﬁt of PD1/PDL1 ICIs in combination
with EGFR-TKI in ﬁrst-line setting (NCT 02039674, NCT02013219,
NCT02143466). Erlotinib plus nivolumab combination resulted in
a tolerable safety proﬁle, with durable responses observed in 4/20
EGFR-mutated, TKI-naïve NSCLC patients(Gettinger, 2014). A phase
III study of osimertinib plus durvalumab has been prematurely
closed because of the high rate of pulmonary toxicities observed
with such combination (NCT 02454933). Finally preliminary results
of the CheckMate 012 study have recently shown a partial response
(PR) in 4/8 EGFR-mutated patients receiving nivolumab plus ipili-
mumab  combination (Hellmann et al., 2016). As suggested by all
these translational and clinical data, more efforts are needed in
order to clarify the complex interaction between EGFR molecular
pathway and anti-tumor immune response, and ultimately select
those patients who may  beneﬁt from these combinations.
4. How to overcome acquired resistance to EGFR-TKIs?
4.1. EGFR-TKI beyond PD
Until one year ago, when radiological progression was detected,
all the international guidelines recommended to continue the
ongoing EGFR-TKI beyond progression disease (PD), with or with-
out loco-regional therapies, except for symptomatic, systemic
PD, which required the immediate switching to platinum-
chemotherapy. The single arm phase II “ASPIRATION” study has
recently demonstrated that continuing erlotinib beyond the radi-
ological PD, would beneﬁt a subgroup of patients with limited
and asymptomatic disease. Particularly 52% of patients clinically
selected by investigators were able to continue TKI after PD, thus
resulting in a 3.1 months longer PFS compared to those who imme-
diately stopped the EGFR-TKI (Park et al., 2016b). Such study,
even if limited by several inherent selection biases, conﬁrmed the
results emerging from several retrospective series, that continu-
ing TKI beyond radiological PD may  represent a reasonable option
in a clinically selected subgroup of patients. However who are
the “selected patients” who may  really beneﬁt from this strat-
egy remains still questionable. Furthermore the results of another
phase III randomized “IMPRESS” study failed to demonstrate any
survival beneﬁt from continuing geﬁtinib beyond PD together with
platinum-chemotherapy compared to switching to chemotherapy
alone. There was no difference in the primary endpoint of PFS
(PFS: 5.4 vs 5.4 months; HR: 0.86, 95%CI: 0.65–1.13), while con-
tinuing TKI resulted in a detrimental effect on OS (OS: 14.8 vs 17
months; HR: 1.62, 95%CI: 1.05–2.52) (Soria et al., 2015). A fur-
ther analysis of survival according to the T790M circulating tumor
(ct) DNA status assessed at baseline revealed that patients with-
out T790M could beneﬁt from combination treatment (PFS: 6.7 vs
5.4; HR: 0.67, 95%CI: 0.43–1.03). However this positive trend in
PFS was  not associated to a signiﬁcant OS improvement, show-
ing HR 1.49 for T790M-positive and HR 1.15 for T790M-negative
patients (Soria et al., 2016). Overall these data suggest that patients
who progressed to prior EGFR-TKI should not continue TKI beyond
PD together with platinum-chemo, because of detrimental effects
observed at least in the T790M positive population, while not
deﬁnitive conclusions may  be drawn for T790M-negative patients.
4.2. New generation EGFR-TKIs
The identiﬁcation of the molecular alterations underlying the
development of resistance has led to the development of several
targeted inhibitors, which are mostly under investigation in clin-
ical studies (Rolfo et al., 2014). The most common mechanisms
of acquired resistance is the secondary T790M point mutation in
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Table 1
Third-generation EGFR-TKIs in clinical development in NSCLC.
EGFR-TKI Dose ORR Toxicity Status
AZD9291 80 mg  QD 61% Diarrhea, rash, nausea, ILD Approved
CO-1686 500 mg  BID 45% Hyperglicemia, nausea, diarrhea Stopped
HM61713 800 mg  QD 43% Diarrhea, rash, nausea, dry skin Stopped
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tEGF816 320 mg/day 44% 
ASP  8273 300 mg  QD 38% 
AC  0010 250 mg  BID 62% 
xon 20 of EGFR gene, described in about 50–60% of cases, fol-
owed by cMET ampliﬁcation (5–15%), Her2 mutations (3–12%),
mall cell lung cancer transformation (3–10%), and others. Partic-
larly, T790M gatekeeper mutation induces both steric hindrance
nd increased binding afﬁnity for adenosine triphosphate (ATP),
hich ultimately results in the reduction of both binding and
otency of reversible EGFR-TKIs. The understanding of such molec-
lar networks accelerated the development of third-generation,
rreversible TKIs, which thanks to their peculiar pyrimidine-based
tructure, are able to target and inhibit not only EGFR activating
utations, but also the resistant T790M mutation (Socinski et al.,
016; Jia et al., 2016). The advent of these drugs in clinical set-
ing produced a paradigm shift in the management of lung cancer
atients who progressed to prior ﬁrst/second-generation TKIs. A
ery promising activity and a tolerable safety proﬁle of such com-
ounds emerged from the phase I studies including patients with
GFR-mutated NSCLC who progressed to ﬁrst-line EGFR-TKI and
ere T790M positive (Table 1). Osimertinib (AZD9291) represents
he compound in most advanced stage of clinical development.
he AURA1 study has ﬁrst shown an impressive ORR: 60%, dis-
ase control rate (DCR): 95%, PFS: 9.6 months with minimal side
ffects in the subgroup of patients with 790M mutation(Skoulidis
nd Papadimitrakopoulou, 2017), leading to the fast-track approval
y regulatory authorities for the treatment of patients who develop
esistance to ﬁrst-generation TKIs and were T790 M positive. The
esults of the phase III randomized AURA3 trial, comparing osimer-
inib vs platinum-pemetrexed chemotherapy in this setting of
atients have been recently reported at the last World Confer-
nce on Lung Cancer (WCLC) 2016 and simultaneously published
n the New England Journal of Medicine (NEJM) (Mok  et al.,
017). The study met  its primary endpoint showing a signiﬁcant
onger median PFS in patients receiving osimertinib compared
o platinum chemotherapy (PFS: 10.1 vs 4.4 months; HR: 0.30,
5%CI: 0.23–0.41), including also the subgroup of patients with
rain metastasis (HR: 0.32, 95%CI: 0.21–0.49). RR were signiﬁ-
antly higher (71% vs 31%), as well as more durable (DoR: 9.7 vs
.1 months) with osimertinib compared to standard chemother-
py. As regards the safety proﬁle osimertinib was associated with
ower rates of G3-4 AEs compared to platinum-pemetrexed. These
mpressive results conﬁrm that osimertinib is the new standard of
are in patients with EGFR-T790 M positive NSCLC who  failed ﬁrst-
ine EGFR-TKI treatment. Indeed all the international guidelines
ave already incorporated osimertinib as recommended option in
his setting. As regards the other new-generation TKIs, unfortu-
ately the clinical development of both rociletinib and olmutinib
as been recently stopped, even if both these agents had already
eceived the FDA-break-through therapy designation in lung can-
er. Despite the promising activity observed in phase I study (Jänne
t al., 2015), the updated “conﬁrmed” response rate to rociletinib
ropped from 59% to 39% at 625 mg  bid dose (n = 175) and to 25%
t 500 mg  bid dose (n = 156) in T790M-positive patients (Sequist
t al., 2015; Goldman et al., 2016). These data, along with the
igh rate of G3-4 hyperglycemia and QTc prolongation reported
n TIGERX trial, led to the FDA notiﬁcation with the subsequent
topping of patients’ enrollment in all ongoing trials with rocile-
inib. Other third-generation TKIs in clinical development includeRash, Diarrhea, stomatitis, pruritus Phase II
Diarrhea, nausea, vomiting, rash, ILD Phase II
Diarrhea, ALT/ASTrash, pruritus, nausea Phase I
EGF816, ASP8273, and AC0010, all showing a great activity and
a tolerable safety proﬁle in phase I studies (Yu et al., 2016; Tan
et al., 2016; Zhang et al., 2016b). However as learned by rocile-
tinib history, a careful evaluation of the results obtained from the
small datasets of early clinical trials is recommended and larger
phase II–III ongoing trials are needed to conﬁrm these preliminary
observations.
5. Which is the current role of liquid biopsy?
5.1. Potential application at diagnosis
The EGFR mutation testing of tumor samples DNA at diagnosis is
recommended by all the international guidelines for advanced non-
squamous NSCLC in order to decide the proper therapeutic strategy
for each patient. Even if tissue biopsy remains the current gold-
standard, however it’s limited by several features, such as the not
easy access to different tumor sites, the invasiveness of procedures,
the tumor heterogeneity, and not ultimately the low patients’
compliance. Thus, in the last decade an alternative not invasive
approach, known as liquid biopsy, has been proposed to overcome
the aforementioned issues. An increasing number of studies and
meta-analysis evaluated the diagnostic value of plasma-based EGFR
testing in the management of NSCLC patients, overall showing a
sensitivity of 0.62 and a speciﬁcity of 0.96 as compared with the
standard tissue genotyping, which suggest an adequate diagnostic
accuracy of circulating tumor (ct)DNA analysis (Qiu et al., 2015; Wu
et al., 2015; Qian et al., 2016; Luo et al., 2014). These evidences have
led to the analytical validation and the clinical approval of EGFR
mutation testing by using ctDNA isolated from plasma or serum of
about 30% of patients whose tissue is not available at diagnosis or
tissue analysis results are not evaluable (Fig. 1). However recent
data have suggested that the ability to identify EGFR activating
mutations in plasma of NSCLC patients is signiﬁcantly higher in the
presence of extra-thoracic (M1b) vs intra-thoracic (M1a) disease,
and it should be taken into account in the clinical management
of our patients (Karlovich et al., 2016; Reck et al., 2016). In the
study of Sacher et al. plasma genotyping by droplet digital PCR
(ddPCR) demonstrated a very high speciﬁcity (100%) and sensitivity
(74–82%) in 80 patients with advanced NSCLC harboring activating
EGFR del19/L858R mutations (Sacher et al., 2016). The open-label
IFUM trial showed a high concordance rate of 94% between plasma-
based (ctDNA) EGFR mutation testing and tissue-based testing in
about 650 patients with EGFR-positive advanced NSCLC (Douillard
et al., 2014). The promising diagnostic performance of ctDNA seen
in this controlled trials was  subsequently conﬁrmed in a real
world diagnostic setting. The multicenter ASSESS study has recently
demonstrated a similar concordance rate of 89% (sensitivity 46%,
speciﬁcity 97%) between these two methods in detecting the EGFR
mutation status in 1162 patients with advanced NSCLC, suggest-
ing the clinical utility and reliability of ctDNA for EGFR mutation
analysis at diagnosis (Reck et al., 2016). However some efforts are
needed to raise the sensitivity of this approach. Despite Real-Time
(RT)-PCR and droplet digital (dd)PCR technologies are most com-
monly used for ctDNA analysis in clinical studies, next generation
sequencing (NGS) is emerging as a very promising tool that can
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llow to overcome several limitations inherent to the other tech-
iques. Indeed there are several commercially available NGS panels
peciﬁcally designed for ctDNA testing in lung cancer, which are
urrently under evaluation in clinical studies. Recently Villaﬂor
t al. assessed the utility of two ctDNA panels in a clinical series
f 68 NSCLC patients; the 54-gene panel include only mutations
hereas the 68-gene include also ALK, RET or ROS1 fusions. In
his paper it was also investigated the concordance between paired
issue and blood samples whenever possible. The results showed
hat 80% of patients have detectable ctDNA, with 83% presenting
t least one non-synonymous ctDNA alteration. As expected the
ost frequent mutations are reported in TP53, KRAS and EGFR
enes. Nevertheless 17% of patients had no ctDNA alterations, even
f for 5 of them an oncogenic driver mutation has been identiﬁed
y tissue-based analysis (Villaﬂor et al., 2016). Therefore we have
o be aware that liquid biopsy analysis may  not always identify
river mutations. Another recent paper evaluated NGS to char-
cterize 112 plasma samples from 102 patients with advanced
SCLC, detecting 275 alterations in 45 genes in 84% of patients (86
f 102). As well as reported in the paper from Villaﬂor (Villaﬂor
t al., 2016), NGS was able to detect mutations in additional genes
or which experimental drugs were available in clinical trials. The
oncordance between tissue and plasma was 79%; interestingly it
ncreased when a shorter time interval between tissue and blood
ollection was reported (Thompson et al., 2016). Finally ct-DNA
nalysis by NGS of over 5000 patients with advanced NSCLC iden-
iﬁed EGFR mutations in about 25% of patients at baseline, thus
ighly consistent with the mutation rate reported by the cancer
enome atlas (TCGA) tissue-based analysis. Furthermore additionaln testing at the time of NSCLC diagnosis.
driver mutations were identiﬁed in about 38% of patients whose
tumor tissue genotyping failed (Mack et al., 2017). Another study
showed a high concordance rate of 88% between urine ctDNA
and tissue genotyping on EGFR-mutation status detection at base-
line, revealing a strong correlation with patients’ outcomes during
EGFR-TKI therapy (Chen et al., 2017). However a standardization
and a prospective validation of ctDNA methodology are required
before its widespread clinical application.
5.2. Potential application at progression
Recently a growing interest has been focused also on monitor-
ing dynamic changes in plasma of both sensitizing and resistant
EGFR-mutations during TKI treatment. Particularly after the clin-
ical approval of osimertinib in United States, Europe and Japan,
re-biopsy at progression became mandatory, in order to iden-
tify T790M mutation or other alternative mechanisms of acquired
resistance and ultimately personalize second-line therapy. Single-
center real-world series demonstrated that repeating tissue biopsy
at the time of PD was  feasible in about 80% of patients with more
than 20% of them having inadequate material for mutation test-
ing and only 30% of patients beneﬁting from such procedure (Yoon
et al., 2012; Chouaid et al., 2014). The non-invasive potential of
ctDNA has been deeply studied by Oxnard in many studies. In 2014,
he ﬁrst demonstrated that the analysis of ctDNA through ddPCR in
serial plasma sampling during TKI treatment, allowed the detection
of the resistance T790M mutation weeks and sometimes months
prior to radiological PD, highlighting the possibility to anticipate
clinical evidence of progression through early molecular evidences
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Oxnard et al., 2014). Recently his group prospectively evaluated
he sensitivity and speciﬁcity of plasma genotyping by ddPCR in 180
atients with advanced NSCLC, including 60 patients with acquired
esistance to EGFR-TKI. Plasma genotyping by ddPCR exhibited 79%
peciﬁcity and 77% sensitivity in the detection of T790M mutation,
hich are lower than those observed with EGFR-activating muta-
ions at baseline (Oxnard et al., 2016). In addition Oxnard et al.
howed that outcomes of T790M-positive patients included in the
hase I AURA study were similar if T790M was detected in plasma
r tumor tissue. Conversely both RR and PFS of T790M-negative
atients on plasma were signiﬁcantly higher than T790M-negative
n tissue, and further tumor genotyping of plasma T790M-negative
atients allowed to identify a subgroup of T790M-positive patients
n tumor tissues who had better outcomes (Oxnard et al., 2016).
ccording to these data the authors suggest that plasma genotyp-
ng could represent the ﬁrst step for the detection of T790M status
t the time of PD. However, because of the low sensitivity (70%)
f the current available technologies which are associated with a
0% false negative rate, patients with T790M-negative on plasma
hould repeat tumor tissue biopsy to further investigate the pres-
nce of such molecular alteration (Fig. 2). Interestingly, 18/164
atients with plasma T790M-positive genotyping were T790M-
egative on tissue analysis, showing favorable clinical outcomes
imilar to those of patients with T790M-positive tumor tissue
Oxnard et al., 2016). These data, consistently with those observed
n other studies evaluating plasma genotyping approach at the
ime of PD (Takahama et al., 2016; Thress et al., 2015), demon-
trated a lower speciﬁcity of plasma-based detection of T790M at
D compared to EGFR-activating mutations detection at baseline,ation testing at the time of NSCLC progression.
likely due to the higher heterogeneity of TKI-resistant tumors. As
single tissue biopsy is just a snapshot of the tumor not reﬂecting
its spatial heterogeneity, ctDNA could be more representative of
the overall tumor mutation status, allowing to identify different
targetable alterations driving tumor resistance. These suggestions
have been recently conﬁrmed by a paper of Chabon et al., who per-
formed CAPP-Seq ctDNA proﬁling on 41 patients harboring both
EGFR-activating and resistant T790M mutations on tumor tissue
after progression to prior EGFR TKI therapy. The CAPP-Seq ctDNA
analysis conﬁrmed a single T790M mutation in 54% of patients,
while revealed additional molecular alterations in 46% of them,
including 34% MET  or HER2 increased gene copy number (GCN),
7% single nucleotide variations (SNVs) in EGFR, PIK3CA, or Rb1,
and 5% both MET  GCN and PIK3CA or Rb1 SNVs (Chabon et al.,
2016). Thus ctDNA genotyping allows to more accurately iden-
tify the presence of potential multiple mechanisms of resistance
emerging during TKI therapy revealing a higher frequency (46%) of
intra-tumor heterogeneity than that (5–15%) reported in previous
studies (Sequist et al., 2011; Yu et al., 2013). Since the co-occurrence
of different molecular alterations has been associated with infe-
rior outcomes to subsequent third-generation TKI therapy, ctDNA
analysis could represent a useful tool to guide the clinicians in
the selection of the best treatment strategy for each patient. In
addition to plasma, urine genotyping has also shown a high sen-
sitivity in detecting T790M mutation status, ranging from 72% to
93%, in preliminary studies including few patients (Reckamp et al.,
2016), and is currently under investigation in trials including larger
cohorts of patients. Interestingly combined plasma and urine test-
ing identiﬁed 12 additional T790M positive patients who  were
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egative on tissue and received beneﬁt from Rociletinib therapy,
nd an early decrease of urine T790M levels was described in 9
atients during such treatment (Reckamp et al., 2016). Notably it
as been recently developed a novel targeted NGS approach for the
etection of both driver mutations and rearrangements in ctDNA
rom advanced NSCLC patients. The assay and analysis software
ere able to identify mutations present at 0.1%, and the diagnos-
ic performance was even better, reaching 100% sensitivity and
peciﬁcity, when mutations were present at an allelic frequency
.4% or greater (Paweletz et al., 2016). The advent of these highly
ensitive technologies offer the opportunity to monitor EGFR-TKI
herapy revealing early dynamic changes in plasma of both sen-
itizing and resistant EGFR-mutations which may  anticipate the
linical/radiological PD. However waiting for analytical and clin-
cal validation of ctDNA in disease monitoring within controlled
rospective trials, the T790M mutation ctDNA analysis with or
ithout complementary tissue biopsy is currently recommended
n all patients who develop radiological PD to prior EGFR-TKI.
. Conclusions
To date we  are witnessing a second revolution in the manage-
ent of EGFR-mutated NSCLC. In this review we have outlined the
ost important innovations emerging from clinical studies. First
nd second generation EGFR-TKIs reached a survival plateau rang-
ng from 21 to 30 months OS in ﬁrst-line, without any signiﬁcant
ifferences observed in direct comparison trials. The addition of
oth anti-angiogenic agents and chemotherapy seem to raise the
ffectiveness of single agent EGFR-TKI, likely thanks to the activity
f early concurrent use of such drugs against de-novo resistance
lterations, but the preliminary results observed in asian popula-
ions need to be conﬁrmed by prospective phase III ongoing studies,
ncluding also caucasian patients. Despite poor outcomes observed
ith single agent ICIs in pre-treated EGFR-mutated patients, an
mproved understanding of the complex interaction between EGFR
olecular pathway and anti-tumor immune response is essential
o identify those patients who could beneﬁt from upfront EGFR-TKI
lus ICI combinations. Third generation EGFR-inhibitors seem to be
ery promising drugs, which thanks to their great activity and tol-
rable safety proﬁle, offer a new potential of cure for patients who
ailed ﬁrst-generation EGFR-TKI and are T790M-positive. Osimer-
inib may  be considered the ﬁrst in class of such new family of
ompounds, as it has been already approved for clinical use, repre-
enting a new available weapon to overcome tumor resistance and
ltimately improve patients’ survival. Promising data have been
bserved also in pre-treated patients with BM,  but randomized
rials in this subset are still ongoing. Results of FLAURA trial will
e crucial to conﬁrm the potential beneﬁt of osimertinib in ﬁrst-
ine. Following the clinical approval of osimertinib re-biopsy at
rogression became mandatory, in order to re-analyze the tumor
olecular proﬁle and identify T790M mutation. In this scenario
tDNA analysis on plasma samples is currently recommended as
rst step of tumor genotyping, followed by tissue biopsy only for
hose patients who are T790M-negative, while EGFR mutation test-
ng by ctDNA at baseline is approved only for a minority of patients
hose tissue is not available at diagnosis or tissue analysis results
re not evaluable. The intratumor heterogeneity found in resistant
SCLC suggests that, thanks to the development of highly sensitive
echnologies, ctDNA genotyping will allow to more accurately iden-
ify the presence of potential multiple mechanisms of resistance
merging during TKI therapy, guiding the selection of the best treat-
ent strategy for each patient. Very exciting is also the promise
f ctDNA in disease monitoring, however there are several issues
hich need to be elucidated and prospective validation is crucial
efore clinical application. Considering the advent of new promis-gy/Hematology 112 (2017) 126–135 133
ing drugs/combinations, the main challenge will be how to combine
all these agents in order to deﬁne the optimal treatment algorithm
and ultimately improve the survival outcomes of EGFR-mutated
NSCLC patients.
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